Sergey Olegovich Gunyakov

Dr. Sergey Olegovich Gunyakov

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2026 in South Russian Journal of Cancer
Verified
Journal Article
Open access
PDF file
ADA. S. Dzasokhov
A. S. Dzasokhov
ESE. Yu. Stolbova
E. Yu. Stolbova
ATA. V. Turiev
A. V. Turiev
VAV. L. Astashov
V. L. Astashov
SGSergey Olegovich Gunyakov
Sergey Olegovich Gunyakov
KIK. B. Ischenko
K. B. Ischenko
Peritoneal carcinomatosis in advanced ovarian cancer is an unfavorable prognostic factor and limits the efficacy of systemic chemotherapy. This provides a rationale for the use of locoregional treatment modalities, including pressurized intraperitoneal aerosol chemotherapy (PIPAC). Of particular interest is the safety of a bidirectional strategy (systemic chemotherapy + PIPAC) in patients requiring multivisceral resection. We present a clinical case of a patient with advanced ovarian cancer and peritoneal carcinomatosis. Induction bidirectional chemotherapy was administered, consisting of paclitaxel/carboplatin (6 cycles) combined with PIPAC using cisplatin 30 mg/m² (50 mg), 30-minute exposure, 3 sessions, followed by multivisceral cytoreductive surgery. Efficacy was assessed based on tumor marker dynamics, peritoneal cancer index (PCI), and morphological response (TRG), while safety was evaluated according to perioperative complications and the feasibility of continuing PIPAC after surgery. At initial laparoscopy in April 2025, peritoneal carcinomatosis was detected (PCI 26); the first PIPAC session was performed, followed by systemic chemotherapy. After the second cycle, a partial response was documented. In June 2025, multivisceral cytoreductive surgery was performed, including anterior resection of the rectum with sigmoid stoma formation. Systemic therapy was resumed early and completed up to 6 cycles. By 20.08.2025, tumor markers had decreased: CA-125 to 47 U/mL, CA 19–9 to 13.7 U/mL, and HE-4 to 120 U/mL. Before PIPAC-2 (September 2025), no macroscopic carcinomato sis was detected (PCI 0); no tumor cells were found in peritoneal biopsy specimens, corresponding to TRG 1. At PIPAC-3 (November 2025), PCI remained 0, and repeat biopsies also corresponded to TRG 1. Induction bidirectional chemotherapy including PIPAC in a patient with advanced ovarian cancer and peritoneal carcinomatosis demonstrated clinical feasibility, safety and marked antitumor efficacy even after multivisceral cytoreduction.

16 June 2026 in P.A. Herzen Journal of Oncology
Verified
Journal Article
Closed access
ADA.S. Dzasokhov
A.S. Dzasokhov
VAV.L. Astashov
V.L. Astashov
AKA.A. Kostin
A.A. Kostin
SGSergey Olegovich Gunyakov
Sergey Olegovich Gunyakov
AKA.V. Khizhnikov
A.V. Khizhnikov
Peritoneal metastases (PM) remain a difficult therapeutic problem with an unfavorable prognosis, mainly due to a poor response to systemic chemotherapy. Intraperitoneal chemotherapy is proposed as an alternative therapeutic method to increase the concentration of the drug in tissues and reduce systemic toxicity. Intraperitoneal pressure aerosol chemotherapy (PIPAC) was introduced in 2011 as an innovative method of intraperitoneal drug delivery in several experimental and clinical studies. As a result, the uncomplicated pilot mastered a combination of methods, the only name of which is “therapeutic pneumoperitoneum”, performed on a pipeline (pressurized intraperitoneal aerosol chemotherapy). In fact, the standard treatment consists of three PIPAC procedures scheduled every 4-6 weeks in combination with systemic chemotherapy, and can be performed depending on tolerability and response to treatment. Prospective and retrospective cohort studies show good tolerability of repeated treatment of PIPAC and rare occurrence of intraoperative and postoperative complications. This study conducted a systematic review to assess the feasibility, safety, and effectiveness of PIPAC.

1 April 2026 in Clinical oncohematology
Verified
Journal Article
Open access
EIE. V. Inyushkina
E. V. Inyushkina
SGSergey Olegovich Gunyakov
Sergey Olegovich Gunyakov
ABA. V. Bogucharskii
A. V. Bogucharskii
VSV. O. Stepanova
V. O. Stepanova
AIM. To assess the therapy outcomes in pediatric patients with acute myeloid leukemias (AMLs) as well as to identify the most important poor prognostic factors and predictors of treatment efficacy. MATERIALS & METHODS. The retrospective analysis includes 35 newly diagnosed AML patients treated at the Moscow Regional Oncology Dispensary from 2018 to 2025. On diagnosis date, the age range was 0 to 17 years (median 7 years). Therapy (standardized induction and consolidation blocks, targeted drugs if needed, and allogeneic hematopoietic stem cell transplantation [allo-HSCT] in first remission) was administered in accordance with risk groups and obligatory monitoring of minimal residual disease (MRD). Clinical and laboratory features, cytogenetic and molecular markers (FLT3-ITD, NPM1, and CEBPA) as well as MRD were assessed after 1–2 courses of induction therapy. The distribution of FAB types was as follows: M7 in 6 (17.1 %), M1 in 5 (14.3 %), M4 in 5 (14.3 %), M5 in 4 (11.4 %), M5a in 4 (11.4 %), and M2 in 4 (11.4 %) cases; other types were detected in 7 (20 %) cases in total. Risk stratification identified 20 (57.1 %) high-, 12 (34.3 %) intermediate-, and 3 (8.6 %) standard-risk patients. RESULTS. At the time of this publication, 21 (60 %) patients are alive, and 14 (40 %) patients have died. The 3-year overall survival was 60 %, and event-free survival (EFS) was 41 %. In the studied cohort of AML patients, early MRD-negative status appeared to be the main predictor of favorable outcome: with MRD ≥ 0.1 % as early as after the first control examination (25.7 % of patients), the number of events significantly increased and long-term rates decreased, whereas achieving MRD-negative status at the end points went hand in hand with the formation of a pronounced plateau on the EFS curve. Clinical and cytogenetic high-risk parameters (FLT3-ITD mutation, hyperleukocytosis at the start, and extramedullary lesions) were associated with earlier unfavorable outcomes and required treatment escalation. The strategy of incorporating allo-HSCT into first-line therapy proved to have outstanding clinical efficacy for high-risk patients and those with MRD persistence. CONCLUSION. The results obtained are consistent with multi-center data on pediatric protocols of AML treatment. This study demonstrated that the risk-adapted therapy taking into account molecular genetic features of the tumor clone as well as MRD monitoring with the routing of patients to allo-HSCT if needed in first complete remission improve long-term survival rates in pediatric AML patients.

16 April 2026 in Endoscopic Surgery
Verified
Journal Article
Closed access
SGSergey Olegovich Gunyakov
Sergey Olegovich Gunyakov
ADA.S. Dzasokhov
A.S. Dzasokhov
MRM.YU. Rykov
M.YU. Rykov
Background. Peritoneal carcinomatosis in children is rare and occurs as a result of the intraperitoneal spread of tumors. Peritoneal carcinomatosis is characterized by extensive damage to the peritoneum, metastases can spread to the abdominal and retroperitoneal lymph nodes, as well as to parenchymal organs such as the liver and spleen. In adult patients, cytoreductive surgery followed by HIPEC and PIPAC techniques can prolong overall and relapse-free survival. The review examines the prospects of using this technology in children. Objective. To evaluate the prospects of using HIPAC and PIPAC in children. Material and methods. A preliminary review of scientific papers published in 2000—2025 in the bibliographic and abstract databases of peer—reviewed scientific literature SinceDirect, Scopus, RSCI was conducted using the following keywords: peritoneal carcinomatosis in children, peritoneal carcinomatosis in adults, PIPAC, HIPEC in children. 8 publications devoted to the effectiveness of treatment of patients with peritoneal carcinomatosis were selected. Results. The main method used in children is HIPEC. The incidence of complications and the effectiveness of treatment are similar to the results in adults. However, this procedure is not possible for all patients. In such cases, the use of PIPEC is advisable, which ensures tumor regression and a long relapse-free period. Conclusion. Peritoneal carcinomatosis is a serious problem and requires the development of modern standardized treatment approaches. HIPEC and PIPEC are self-contained methods and can be used interchangeably in certain cases. However, it is necessary to develop a protocol that will allow stratification of patients at different stages of treatment in order to select the appropriate method in a particular case.

22 April 2026 in Bone and soft tissue sarcomas, tumors of the skin
Verified
Journal Article
Open access
PDF file
SGSergey Olegovich Gunyakov
Sergey Olegovich Gunyakov
EIE. V. Inyushkina
E. V. Inyushkina
AKA. V. Khizhnikov
A. V. Khizhnikov
VSV. O. Stepanova
V. O. Stepanova
MRMaxim Yu. Rykov
Maxim Yu. Rykov
Introduction. Epithelioid sarcoma is a rare malignant tumor of the soft tissues developing mostly in young adults. In children this pathology is diagnosed very rarely which often leads to its late verification and unplanned surgical interventions aimed at tumor resection which at early stages is mistaken for a benign neoplasm. The main difficulties are associated with non-specificity of the clinical presentation and the necessity of using immunohistochemical and molecular methods for establishment of the final diagnosis. The article describes a clinical case of diagnosis and treatment of epithelioid soft tissue sarcoma in a child; difficulties of diagnosis associated with morphological verification and differential diagnosis of this tumor are presented, and efficacy of combination treatment consisting of radical surgical intervention and adjuvant radiotherapy is analyzed. Clinical case. A boy, 11 years old, with epithelioid sarcoma of the soft tissues of the right shoulder. For diagnosis, medical history, clinical examination and instrumental methods – ultrasound, magnetic resonance tomography and computed tomography of the thoracic cage and abdomen, scintigraphy and positron emission tomography/computed tomography were used. Additionally, bone marrow biopsy to exclude systemic tumor advancement was performed. Treatment included radical surgical tumor resection with defect reconstruction and subsequent adjuvant radiotherapy at the tumor bed. Efficacy of the therapy was evaluated based on clinical data and results of dynamics in control examinations. No serious complications were reported, local control was achieved, as well as good quality of life of the child in short-term observation period. Conclusion. The presented clinical case demonstrates difficulties of early diagnosis of epithelioid sarcoma in children, adds to the current clinical base, and has practical value for improvement of management of patients of pediatric age with rare tumors of the soft tissues.

23 June 2026 in Research and Practical Medicine Journal
Verified
Journal Article
Open access
PDF file
ADA. S. Dzasokhov
A. S. Dzasokhov
VAV. L. Astashov
V. L. Astashov
SGSergey Olegovich Gunyakov
Sergey Olegovich Gunyakov
ATA. V. Turiev
A. V. Turiev
Purpose of the study. To assess the dynamics of the Peritoneal Adhesion Index (PAI) and the number of involved anatomical regions of the abdominal cavity in patients with ovarian cancer and peritoneal carcinomatosis during consecutive sessions of pressurized intraperitoneal aerosol chemotherapy (PIPAC). Patients and methods. A single-center observational study with intraoperative assessment of adhesive status was performed in 87 patients. PAI and the number of involved abdominal regions were determined during three PIPAC sessions and at delayed diagnostic laparoscopy. Available completed paired observations were used for interval comparisons. The primary endpoint was the change in total PAI; secondary endpoints were changes in the number of involved regions and the overall direction of changes by the time of delayed laparoscopy. The statistical significance of paired changes was assessed using the sign test. Results. Between the 1st and 2nd PIPAC sessions, a decrease in PAI was recorded in 57 patients (65.5 %), no change in 24 (27.6 %), and an increase in 6 (6.9 %); the mean change was – 2.7 points (p < 0.0001). Between the 2nd and 3rd PIPAC sessions, a decrease in PAI was observed in 35 patients (38.9 %), no change in 53 (58.9 %), and an increase in 2 (2.2 %); the mean change was 0.89 points (p < 0.0001). Between the 3rd PIPAC session and delayed laparoscopy, a decrease in PAI was observed in 14 patients (16.1 %), no change in 70 (80.5 %), and an increase in 3 (3.4 %); the mean change was 0.10 points (p = 0.006). Overall, a decrease in PAI from baseline to delayed laparoscopy was recorded in 56 patients (64.4 %), no change in 22 (25.3 %), and an increase in 9 (10.3 %); the mean cumulative change was 3.7 points (p < 0.0001). A similar pattern was observed for the number of involved regions: an overall decrease was recorded in 54 patients (62.1 %), no change in 24 (27.6 %), and an increase in 9 (10.3 %); the mean cumulative change was 1.32 points (p < 0.0001). Conclusion. The sequential use of PIPAC was associated with a reduction in the severity and extent of abdominal adhesions, indicating a favorable safety profile of PIPAC and the technical feasibility of repeated laparoscopic procedures.